USP <800>: The Mindset of Readiness
Acquiring expertise on proper aseptic processes that significantly enhance the quality of your compounding practices and the safety of your CSPs.
Introduction:
In this three-part blog series, we explore essential tips and tools to perform mock inspections within compounding environments and the benefits they offer such as pharmacist confidence and organization readiness.
Mock Inspections: Not Fear –– but Alertness
An inspection should not trigger fear. It should trigger alertness. When conducted properly, a mock inspection helps:
- Rank operations against objective standards.
- Identify gaps before they become citations.
- Dismiss assumptions with data.
- Strengthen compliance posture.
- Improve patient safety culture.
Know “Who’s” Coming –– and Why
The Joint Commission
In pharmacies, TJC focuses heavily on Medication Management (MM) standards, patient safety, labeling, storage, preparation processes, and error prevention systems. Therefore, all aspects of sterile product compounding (cradle to grave), patient and medication safety, storage, disposition, and other aspects of components as well as finished products will all be considered and scored. Additionally, cleanroom management and staff competencies will be weighted as an application of medication management standards.
State Board of Pharmacy
Typically, the Board views USP <797> compliance as minimum standards required for licensure. Since the state boards have the charge to regulate compounding, they will determine if licensure requirements are adhered to according to board rules. Their inspection checklist will have all critical aspects of sterile compounding and will be graded usually as a “yes” or “no” score. Corrective actions are expected within a thirty-day window. Shutdown or category downgrades may result during a state board inspection.
- Personnel competency
- Environmental monitoring
- Certifications
- Documentation integrity
- Corrective and preventive actions documentation.
- Others
Complaint-Based Inspections and Inquiries
Partnering With Quality –– But Leading the Standard
Common Mistake: “Inspection Window Behavior”
Patch-Ups vs Cover-Ups – The Difference Between the Two
There will always be appropriate opportunities to fine‑tune a compounding operation in preparation for an inspection. When done correctly, these actions reflect routine maintenance, operational discipline, and professional pride rather than attempts to obscure deficiencies.
Appropriate Patch-Ups
- Repairing physical damage
- Painting walls
- Organizing shelves
- Repairing worn flooring
- Inserting tabs on binders to make it easier to find details
- Redoing a failed competency if not already done
- Calibrating monitors
- Others
These signal maintenance and pride.
Dangerous Cover-Ups
- Backfilling documentation with fabricated data
- Using white-out
- Concealing recurring issues
- masking patterns instead of addressing root causes undermine compliance and credibility.
If there is a documentation gap:
- Organizations should correct them transparently by entering accurate, retrievable data when appropriate
- Initial and date corrections transparently.
- initiate a CAPA when required to address gaps or breaches
Integrity builds credibility. Cover-ups destroy it.
Review Historical Data
Effective mock inspections begin with a thorough review of historical data.
- Previous Board of Pharmacy reports
- Previous Joint Commission findings
- Internal audit results
- Environmental monitoring trends
- Recurrent CAPAs
Integrity in Leadership
Mock inspections are not about catching staff doing something wrong. They are about strengthening the system so staff can do things right — consistently. If readiness only appears during inspection season, it is not readiness. It is reaction.
In the second blog article of this three part blog series, we will move from mindset to mechanics — walking through the structural elements of a USP <797>/<800> internal mock inspection. For more information, refer to the references found below (Note: This will be the only references provided for the three-part series).
References
United States Pharmacopeia (USP)
- USP <797> Pharmaceutical Compounding—Sterile Preparations. Revised 2023. Official November 1, 2023.
- USP <800> Hazardous Drugs—Handling in Healthcare Settings.
- USP <795> Pharmaceutical Compounding—Nonsterile Preparations. Revised 2023.
These standards form the technical and operational foundation for:
- Designated Person accountability
- Personnel competency
- Environmental monitoring
- Documentation integrity
- Governance and oversight
Accreditation & Medication Management Standards
The Joint Commission
- Comprehensive Accreditation Manual for Hospitals (CAMH).
- Medication Management (MM) Standards
- MM.05.01.07 – Compounding sterile preparations.
- MM.05.01.09 – Labeling requirements
- MM.08.01.01 – Storage and security of medications
- Environment of Care (EC) Standards
These standards support the blog’s discussion regarding:
- Inspection focuses on differences.
- Medication safety emphasis
- Tracer methodology
- Continuous readiness posture
Federal Oversight of Accrediting Organizations
Centers for Medicare & Medicaid Services (CMS)
- State Operations Manual (SOM)
- Conditions of Participation for Hospitals (42 CFR §482)
- CMS Deeming Authority Requirements for Accrediting Organizations
These documents support discussion around:
- Validation surveys
- Oversight of accrediting bodies
- Regulatory alignment
Hazardous Drug & Safety Guidance
National Institute for Occupational Safety and Health (NIOSH)
- NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings (2023).
- NIOSH Alert: Preventing Occupational Exposure to Hazardous Drugs (DHHS 2004-165).
Occupational Safety and Health Administration (OSHA)
- 29 CFR 1910.1450 – Occupational Exposure to Hazardous Chemicals in Laboratories
- OSHA Technical Manual, Section VI, Chapter 2 (Hazardous Drugs)
Professional Practice Guidance
American Society of Health-System Pharmacists (ASHP)
- ASHP Guidelines on Compounding Sterile Preparations (Am J Health-Syst Pharm. 2014;71:145–166).
- ASHP Guidance on Handling Hazardous Drugs (Am J Health-Syst Pharm. 2006;63:1172–1193).
These references support the blog’s emphasis on:
- System strengthening
- Governance structures
- Leadership responsibility in sterile compounding
Environmental & Infection Control References
Centers for Disease Control and Prevention (CDC)
- Guidelines for Environmental Infection Control in Health-Care Facilities (updated 2019).
- Guidelines for Hand Hygiene in Health-Care Settings (MMWR 2002;51[RR-16]).
ANSI/ISEA Z358.1-2014
Seven97 Training Insight
Released March 2026
About the Author
Luis Hernandez, RPh, BCSCP, is a certified sterile compounding pharmacist and the founder of Seven97 Training Solutions. Dedicated to advancing USP 797 pharmaceutical training, validation, and certification, Luis aims to promote and inspire excellence in aseptic processing, medication and patient safety, and regulatory compliance.